Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Completed 2Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 106Head & Neck 21Gynecologic 20Genitourinary 19Endocrine 17Thoracic 16Tumor-Agnostic 7Other solid neoplasm 7Dermatologic 7CNS 7Breast 6NET 5Sarcoma 3

Conditions

Neuroendocrine Tumors 5Multiple Endocrine Neoplasia Type 1 1Carcinoma, Neuroendocrine 1

Interventions

lutetium Lu 177 dotatate 18Everolimus 13Temozolomide 12Nivolumab 10pembrolizumab 9cabozantinib 8Capecitabine 8Sunitinib 7lenvatinib 5Magnetic Resonance Spectroscopy 5Etoposide 5lanreotide 4gallium Ga 68 dotatate 4Specimen Handling 4Ipilimumab 4Cisplatin 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4telotristat ethyl 3surufatinib 3pazopanib 3avelumab 3Octreotide 3Injections 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Bevacizumab 3sintilimab 2fosbretabulin 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × lenvatinib × NET × Clear all
NCT04848337 2026-05-11

PLANE-PC

University of Michigan Rogel Cancer Center

Phase 2 Active not recruiting
45 enrolled 8 charts
EndocrineNET

Neuroendocrine Tumors

NCT03950609 2026-03-19

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
36 enrolled
EndocrineNET

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT05746208 2026-03-17

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

University of California, San Francisco

Phase 2 Recruiting
29 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03290079 2025-12-22

Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
20 enrolled 12 charts
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT02678780 2025-07-24

TALENT

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
123 enrolled 37 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡